Oncoletter
Navigation überspringen
  • Kongressberichte & Archiv
    • SABCS - 41th Annual San Antonio Breast Cancer Symposium
      • Press Conferences
        • Wednesday, Dec. 5, Press Conference 1
        • Wednesday, Dec. 5, Press Conference 2
        • Thursday, Dec. 6 Press Conference
        • Friday, Dec. 7 Press Conference
      • Schweizer Poster am SABCS
      • Interviews - Breast Cancer
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Achim Rody, Lübeck
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle/Saale
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Priv.-Doz. Dr. med. Hans-Christian Kolberg in Bottrop
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Sibylle Loibl, Frankfurt
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. Rachel Würstlein, München
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Jörg Schilling, Berlin
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Priv.-Doz. Dr. med. Hans-Christian Kolberg, Bottrop
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Lothar Müller, Onkologie Unterems
      • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
      • Round Table mit Brustkrebs Deutschland e.V.
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
    • American Society of Hematology (ASH) 60th Annual Meeting and Exposition
      • Statements & Opinions from some Highlights of the Conference
      • Press Briefings
        • Saturday December 1
          • Improving Sickle Cell Disease Outcomes in the U.S. and Africa
          • Major Trials Show Benefits of New Therapy Regimens for Cancer and Blood Disorders
          • CAR T-Cell Therapies: New Research and Updates from Pivotal Trials
        • Sunday December 2
        • Monday December 3
          • Late-Breaking Abstracts - Non-Malignant
          • Late-Breaking Abstracts - Malignant
      • Late-Breaking Abstracts Session
      • Myeloma: Therapy and upfront autologous Transplantation
        • Novel Antibody Combinations in Myeloma
        • Novel Targeted Combinations in Myeloma
        • Antibodies and Targeted Therapies
        • Novel Proteasome Inhibitors
        • Immunotherapies in Plasma Cell Disorders
        • Immunotherapy
        • Upfront Autologous Transplantation
      • Choice of Myeloma Posters
      • Acute Myeloid Leukemia - Clinical Studies
        • Immunotherapy and New Agents
        • Minimal Residual Disease and Genetic Characterization
        • Maintenance after Allogeneic Stem Cell Transplant and Management of Refractory/Relapsed AML
      • Acute Myeloid Leukemia - Commercially Available Therapy, excluding Transplantation:
        • Optimal Induction and Re-Induction Regimens For Acute Myeloid Leukemia
        • Targeted Therapy For Adults Diagnosed With Acute Myeloid Leukemia
      • Acute Myeloid Leukemia - Novel Therapy, excluding Transplantation
        • Combination Therapy
        • Targeted Therapy
        • New Treatment Strategies
        • Immunotherapy
      • Acute Lymphoblastic Leukemia: Clinical Studies & Therapy Excluding Transplantations
        • Improving Outcomes with Cellular Therapy
        • Improving Frontline Therapy in ALL
        • Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next?
        • Targeted Therapy in ALL: Immunotherapy and Beyond
      • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
        • Prognostic Markers and Therapies in Mantle Cell Lymphoma and Waldenstrom's Macroglobulinemia
        • Novel Therapies and Prognostic Assessment in Hairy Cell Leukemia and Indolent Non-Hodgkin Lymphoma
        • Antibodies, Immunomodulators, and BTK Inhibitors in Indolent NHL
      • Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
        • Immunotherapy and Targeted Strategies
        • Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches
        • T Cell Lymphoma: Chemotherapy and Targeted Approaches
      • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials
        • Immunotherapy
        • New Agents
        • Initial Treatment
      • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies
        • Outcomes With CD19 CAR T Therapy and Checkpoint Blockade in the Real World Setting
        • Prognostic Biomarkers and Molecular Signatures for Risk Stratification
        • Population Based Outcomes in Aggressive Lymphoma
        • Outcomes Of Lymphoma In The Elderly
      • Chronic Myeloid Leukemia: Therapy
        • Epidemiology, Prognosis, and Real Life Care
        • First Line Trials and Prognostic Factors of Treatment-Free Remission
        • TFR Failure, Resistance, and New Drug Development
      • Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics, Prognosis and Prediction
        • Novel Therapeutics I
        • Novel Therapeutics II
        • Prognosis and Prediction
      • CLL: Therapy, excluding Transplantation:
        • Measurable Residual Disease in CLL: Moving Towards a Cure
        • Cellular Therapy and Immunomodulation in CLL
        • Advances in CLL Using Novel Combination Therapy
      • Health Services & Outcome Research—Malignant Diseases
      • Clinical Trials for Hemophilia and Using CAR T Cells
      • Thalassemia and Globin Gene Regulation
    • Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
    • ESMO 2018 Congress
      • Press Briefings
        • Breast Cancer
        • Ovarian Cancer
        • Prostate & Kidney Cancers
        • Head & Neck Cancer
        • All ESMO 2018 Press Releases
      • Interviews
        • Interviews - Breast Cancer
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Sven Mahner, München
        • Statement Summary GIT-Cancers
        • Statements Colorectal Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Gastric Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Lung Cancer
        • Statement Renal Cell Carcinoma
      • Links to selected presentations and abstracts
        • Presidential Sessions
          • Presidential Session 1
          • Presidential Session 2
          • Presidential Session 3
        • Selection of Posters
          • 464P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
          • 1290P - Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): experience from an ad hoc expanded access program (EAP)
          • 509P - Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): a FIRE-3 analysis
          • 481P - Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial
          • 549P - Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: the plasma RAS wild type “window of opportunity”
          • 1068P - Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), a phase Ib – randomized phase II study versus single agent MTX
    • Cancer Academy - Blut- und Lymphdrüsenkrebs
    • Comprehensive Cancer Center Zürich: Third Zurich Immuno-Oncology Symposium
      • Keynote address
      • Clinical results, patient cases and future developments I
      • Clinical results, patient cases and future developments II
      • Clinical results, patient cases and future developments III
      • Developments in immunotherapy
    • 20th World Congress on Gastrointestinal Cancer (WCGIC 2018)
      • Session I: Welcome with Selected Abstracts
      • Session II: Cancer of the Pancreas and Biliary Tract - Selected Abstracts
      • Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer
      • Pancreatic Cancer: Poster Session
      • Session VII: Gastric Cancer: Presentation of selected abstracts
      • Session VIII: Diseases and Cancers of the Liver: Presentation of a selected abstract
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer
      • Session XX: Colorectal Cancer: Presentation of selected abstracts
    • 23rd Congress of EHA
      • Presidential Symposium
      • Plenary Session Abstracts
      • Press Briefings
        • Press Briefing Day 1
        • Press Briefing Day 2
      • Important AML Presentations
        • IDHm and BCL2 inhibitors in AML
        • One AML Poster
      • Important CLL Presentations
      • Important Multiple Myeloma Presentations
        • Advances in front-line treatment of newly diagnosed multiple myeloma
        • New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders
        • Multiple Myeloma Poster Presentations
        • One Multiple Myeloma Late Breaking Abstract
      • Important Lymphoma Presentations
      • Thalassemia (2 Presentations) & MDS (1 Presentation)
    • Annual Meeting of the American Society of Clinical Oncology 2018
      • Highlights of the day
        • Sunday
        • Monday
        • Tuesday
      • Press Briefings
        • May 16 Presscast
        • Press Briefing 1 Friday June 1:
        • Press Briefing 2 Saturday June 2:
        • Press Briefing 3 Sunday June 3:
        • Press Briefing 4 Monday June 4:
      • Breast Cancer
        • Breast Cancer News from Oral Sessions
        • Breast Cancer News from Poster Sessions
        • Breast Cancer News Interviews
      • Colon Cancer
        • Colon Cancer News from Poster Sessions
      • Lung Cancer
        • Lung Cancer News from oral sessions
      • Lymphoma
        • Lymphoma News Oral Sessions
        • Lymphoma News Poster Sessions
      • Merkel-Cell Carcinoma
      • Myeloid Diseases
        • Myeloid Diseases News from Oral Sessions
        • Myeloid Diseases News from Poster Sessions
      • Other Hematologic Malignancies
      • Pancreatic Cancer
        • Pancreatic Cancer News from Oral Sessions
        • Pancreatic Cancer News from Poster Sessions
      • Urologic Cancers
        • Renal Cancer
    • ESMO Preceptorship on Colorectal Cancer 2018
    • SENOLOGIE update 2018
      • Prophylaktische Mastektomie - Moderation: M. Knauer, St. Gallen
      • Psychosoziale Konsequenzen des Mammakarzinoms - Moderation: E. Sarasin, Zürich
      • Update Systemtherapie - Moderation: U. Breitenstein, Zürich
      • Varia - Moderation: E. Saurenmann, Zürich
    • Cancer Academy - Darmkrebs
    • AACR Annual Meeting 2018, April 14-18,
      • Highlights presented at the Press Conference Sunday, April 15
      • Highlights presented at the Press Conference Monday, April 16
      • Highlights presented at the Press Conference Tuesday, April 17
    • ELCC 2018 (European Lung Cancer Congress)
      • Highlights - Press Releases
      • Interviews
        • Conference Highlights
        • Interviews in Cooperation with the Video Journal of Oncology - Part 1
      • SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
    • 11th European Breast Cancer Conference (EBCC-11)
      • Press conferences
      • Important News
      • Interviews
        • PD Dr. med. Christian Kolberg, Bottrop
        • Prof. Dr. med. Thorsten Kühn, Esslingen
        • Prof. Dr. med. Nadia Harbeck, München
    • St. Gallen International Gastrointestinal Cancer Conference Primary Therapy of Early GI Cancers -
      • Session 1: Oesophago-Gastric Cancer: One Disease or Separate Entities?
      • Session 2: Treatment of Oesophago-Gastric Cancer: Setting the Stage – Who Benefits from Multimodal Therapy
      • Session 3: Treatment Modalities for Oesophago-Gastric Cancer
      • Session 4: Special situation I: Signet Ring Cell Cancer
      • Keynote: Hereditary Gastric Cancer
      • New Therapy Options by metastatic Colorectal Cancer
      • Session 5: Special situation II: Limits of Curative Approaches to Metastatic Oesophago-Gastric Cancer
      • Session 6: Ready for Practice?
      • EORTC Gastrointestinal Tract Cancer Group:
    • Cancer Academy - Prostatakrebs
    • Promoting Self-efficacy with Digital Tools
      • Welcome (German)
      • Promoting patients’ self-efficacy: How can it be successful? (German)
      • United Kingdom’s perspective on the use of digital solutions to improve cancer patients’ self-efficacy
      • Presentation of selected digital and patient-oriented applications
        • Consilium: Patient-centered communication for improved self-efficacy and quality of life
        • STREAM – Ein online Programm zur Unterstützung bei Belastung während einer Krebserkrankung
        • Symptom Navi: Förderung des Selbstmanagements von Symptomen bei Krebs
        • Entspannung und Achtsamkeit für Krebspatienten mit Hilfe einer App (CanRelax)
        • FertiOnco – an online approach to facilitate decision making in young female cancer patients regarding fertility preservation
      • The use of patient-reported outcomes to improve outcomes and quality in cancer care
      • Digital solutions for cancer patients: reach, (cost-) effectiveness and implementation
      • Discussion and Closing remarks (German)
    • Gastrointestinal Cancers Symposium Jan 18-20, 2018 San Francisco, California
      • Cancers of the Esophagus and Stomach
      • Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
        • Videostatements
        • Studies presented in oral sessions
        • Posters
        • Posters
      • Cancers of the Colon, Rectum, and Anus
        • Videostatement
        • Studies presented in oral sessions
        • Choice of Posters
    • 59th ASH Annual Meeting and Exposition
      • Late-Breaking Abstracts Session
      • AML
        • Oral Sessions
          • Acute Myeloid Leukemia: Clinical Studies: Advances in Frontline Therapy: Induction, Consolidation, and Maintenance
          • Acute Myeloid Leukemia: Clinical Studies: Novel Therapies for AML and APL
          • Acute Myeloid Leukemia: Clinical Studies: Risk Factors and Response-Adapted Personalized Medicine
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Emerging Molecularly-Targeted Therapies in AML
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Therapies for Elderly Patients with AML
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targeted and Immune-based Approaches in the Treatment of AML
      • Multiple Myeloma
        • Oral Sessions
          • Myeloma: Therapy, excluding Transplantation: Upfront Therapy for Multiple Myeloma: Induction and Maintenance
          • Myeloma: Therapy, excluding Transplantation: Immunotherapy in Myeloma and Amyloid
          • Studies in Relapsed and Refractory Multiple Myeloma
          • Myeloma: Therapy, excluding Transplantation I
          • Myeloma: Therapy, excluding Transplantation II
        • Choice of Posters
      • Lymphoma
        • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Clinical Studies: Mantle Cell Lymphoma, New Therapies
          • Indolent Lymphomas, Novel Therapies, and Diagnostics
          • Follicular Lymphoma, First Line
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Novel Agents and Upfront Approaches
          • Immune-Based Therapeutic Approaches
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Predicting Efficacy and Safety of CAR-T cells and Checkpoint Blockade
          • Outcomes in Rare Entities: HTLV-1 ATLL, Gray Zone Lymphoma, Primary CNS Lymphoma, and Intravascular DLBCL
          • Molecular Characterization of Diffuse Large B Cell Lymphoma
          • PET-Guided Therapy and Prognostic Models in Diffuse Large B-Cell Lymphoma
        • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • Hodgkin Lymphoma Immunotherapy Studies; nodular lymphocyte predominant Hodgkin lymphoma clinical studies
          • Hodgkin Lymphoma—Chemotherapy and PET Studies
          • T-Cell Lymphoma Clinical Studies
        • CLL: Therapy, excluding Transplantation:
          • Targeting MRD Negative CLL Through Combinations of Novel Agents and Antibody
          • Targeting MRD Negative CLL with Combinations of Novel Agents and Chemoimmunotherapy Regimens, New Treatments
          • New Agents, Infections, and PET/CT
      • Press Conferences
        • Novel Approaches to Hemophilia and Venous Thromboembolism Care
        • Engineering Solutions to Treat Inherited Blood Disorders
        • Enhancing Care in Hematologic Malignancies through Targeted Therapies
        • Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies
        • Late-Breaking Abstracts
      • Interviews
        • Statement Christian Taverna, Münsterlingen
        • Statement Thorsten Zenz, Zürich
    • 40th Annual San Antonio Breast Cancer Symposium (SABCS)
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
      • Press Conferences
        • Wednesday December 6 @ 7:15 a.m.
        • Wednesday December 6 @ 12:15 p.m
        • Thursday December 7 @ 7:30 am
        • Friday December 8 @ 7:30 am
      • Interviews & Brustkrebs Deutschland Round Table & SAKK Roundtable
        • Roundtable Brustkrebs Deutschland
        • Roundtable mit Experten aus der Schweiz
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin (Kopie)
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Stefan Buchholz, Regensburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Thorsten Kühn, Esslingen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Dr. phil. Ute Berndt, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr.med. Michael Untch, Berlin-Buch
    • Cancer Academy – Hirntumoren
    • 7. Interdisziplinäres Prostatakarzinomsymposium
      • Grundlagen
      • Lokalisiertes & oligometastatisches Prostatakarzinom
      • Systemtherapien Prostatakarzinom
    • Advanced Breast Cancer 4th ESO-ESMO International Consensus Conference
    • Cancer Academy – Brustkrebs
    • ESMO 2017 Congress
      • Breast Cancer Highlights
        • Neoadjuvante Therapie bei luminalem, triple negativem oder HER2 positivem Brustkrebs
        • Luminaler Brustkrebs - wer braucht Chemotherapie?
        • CDK4-6 Inhibitoren beim metastasierten Brustkrebs
        • Abstract LBA10_PR ‘Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)’
        • Abstract 1472P_PR ‘Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients’
      • Gastrointestinal Carcinoma Highlights
        • Colorectal Cancer
          • Summary Statement
          • 593P - Quality of life (QoL) analyses in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with first-line FOLFOX-4 ± cetuximab in the phase 3 TAILOR trial
          • Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) mCRC patients treated with FOLFIRI plus cetuximab in the CAPRI-GOIM trial
        • Gastric Cancer
      • Head & Neck Cancer Highlights
        • PD Dr. med. Sacha Rothschild comments Head&Neck Cancer Studies
        • Abstract LBA45_PR ‘Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial’
        • 1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
        • 1. First line Cetuximab and Cisplatin with or without Paclitaxel/2. The observational ENCORE study: Cetuximab + platinum-based therapy
      • Lung Cancer Highlights
        • Prof. Martin Reck
        • PD Dr. AlessandraCurioni-Fontecedro
        • PD Dr. AlessandraCurioni-Fontecedro
        • Prof. Dr. med.Solange Peters
        • Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
      • Melanoma & Merkel Cell Carcinoma Highlights
        • Prof. Dr. med. Reinhard Dummer, Zurich
        • Prof. Dr. med. Olivier Michielin, Lausanne
      • Ovarian Cancer Highlights
      • Urogenital Cancer Highlights
        • Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights
        • Abstract LBA37_PR – ‘Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial’
      • Late breaking news
        • Opening Press Conference
        • LBA Press Conference: Lung cancer
        • Press Conference: Facing the challenges of life after cancer
        • LBA Press Conference: Breast cancer, Gynaecological cancers, Genito-urinary cancers
        • LBA Press Conference: Melanoma cancer
        • Wrap-Up press conference/Best of ESMO2017
    • Cancer Center Zürich Second - Zurich Immuno-Oncology Symposium
      • Welcome
      • Essentials of tumour immunology and immunotherapies
      • Clinical results, patient cases and future developments I
      • Clinical results, patient cases and future developments II
      • Clinical results, patient cases and future developments III
      • Management of toxicities
    • ESMO 19th World Congress on Gastrointestinal Cancer
      • Cancer of the Pancreas
        • Session II: Cancer of the Pancreas & bile Ducts
        • Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology
        • Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
        • Interview mit Prof. Gerald Prager, Wien
      • Colon Cancer Highlights
        • Session XIX: Colorectal Cancer
        • Prof. Dr. med. Bernhard Pestalozzi, UniversitätsSpital Zürich:
    • Die besonderen Bedürfnisse von Kindern und Jugendlichen mit Krebs
    • 14 The International Conference on Malignant Lymphoma (ICML)
      • Interviews & Introductory Press Conference
        • Introductory Press Conference
        • Lymphoma Therapy
        • Oncoletter Interviews in cooperation with VJHEMONC
      • Satellite Symposia
        • THE FIRST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
        • CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?
    • ASCO Annual Meeting 2017
      • ASCO Press Conferences
        • ASCO Annual Meeting 2017 Presscast May 17
        • ASCO Annual Meeting 2017 Presscast June 2
        • ASCO Annual Meeting 2017 Presscast June 3 Part 1
        • ASCO Annual Meeting 2017 Presscast June 3 Part 2
        • ASCO Annual Meeting 2017 Presscast June 4
        • ASCO Annual Meeting 2017 Presscast June 5
      • Online-Programm verbessert die Lebensqualität von Krebspatienten
      • Highlights Mammakarzinom
        • Brustkrebs Deutschland: Experten-Roundtable vom ASCO Annual Meeting 2017
        • HER2-positiver, primär metastasierter Brustkrebs
        • HER2-positiver metastasierter Brustkrebs
        • PARP-Inhibitoren bei Brustkrebs
        • Abemaciclib bei Brustkrebs-Hirnmetastasen
        • HER2-positiver, primär metastasierter Brustkrebs
        • Scalp-Cooling - Chemo ohne Haarverlust?
        • CDK 4-6 Inhibitoren: Palbociclib, Ribociclib, Abemaciclib
        • Ergebnisse der Aphinity-Studie für HER 2 neu-positiven Brustkrebs adjuvant
        • Stellungnahme zur Relevanz von Studienendpunkten und deren Akzeptanz am runden Tisch: Wir alle müssen umdenken!
        • Finale Ergebnisse der PlanB-Studie für klinische Hochrisikopatientinnen bzw. mit mittlerem bis hohem Risiko nach Genexpressionstest
        • Short-HER-Studie:Sind 9 Wochen Trastuzumab nicht schlechter als 1 Jahr?
        • I-Spy 2-Studie: Immuntherapie mit Pembrolizumab plus Standard neoadjuvante Therapie für Hochrisikopatientinnen
      • Highlights Ovarialkarzinom
        • LION Studie: Rolle der Lymphknotenentfernung bei Erstoperation des Eierstockkrebs
        • DESKTOP 3 Studie: Erneute OP beim Eierstockkrebs Rezidiv
        • Immuntherapie bei Vulva-, Zervix- und Ovarialkarzinom: gibt es schon Einsatzmöglichkeit?
        • PARP-Inhibitoren beim Eierstockkrebs: welcher, wann und wie lange?
      • Head & Neck Cancer Highlights
        • Highlights Head&Neck
        • Statements Sacha Rothschild, Jean Bourhis & Marco Merlano
        • Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)
      • Highlights Gastrointestinaltumoren
        • Upper GIT
        • Colon Cancer
          • Colon Cancer Highlights
          • Role of Cetuximab
        • Pancreatic Cancer
      • Haematologic Malignancies
    • ELCC 2017 Genf
    • Cancer Academy – Lungenkrebs: Früherkennung, Diagnose und Behandlung
    • SENOLOGIE update 2017
      • Radiologie - Moderation: F. Dammann, Zürich
      • Genetik - Moderation: R. Morant, Rapperswil
      • Qualitätssicherung in der Senologie - Moderation: C. Rageth, Zürich
      • Operative Therapie - Moderation: C. Tausch, Zürich
      • Das metastasierte Mammakarzionom - Moderation: A. Müller, Winterthur
      • Varia - Moderation: D. Fink, Zürich
    • 15th St.Gallen International Breast Cancer Conference
    • Symposium Thoracic Oncology – Guidelines and Beyond
      • Screening
      • Inquiring the molecular tumor characteristics
      • Shanghai meets Zürich
      • Treatment options in localized NSCLC
      • Multimodality approaches in rare thoracic tumors
      • Metastatic disease
    • Archiv 2016
      • Das elektronische Patientendossier: das Genfer Beispiel der Integration eines Spitals in eine Referenzgemeinschaft
      • IASLC 17TH WORLD CONFERENCE ON LUNG CANCER
        • Fachpressemitteilungen
          • Lungenkrebs-Weltkongress in Wien: Aktive Prävention, akkurate Diagnostik, aktuelle Fortschritte in der Behandlung
          • Mutations-Diagnostik setzt sich bei Lungenkrebs durch
          • Mikro-RNA zur Prognosebestimmung bei Mesotheliom-Erkrankungen
          • Therapeutische Impfung gegen Lungenkrebs:
          • Zweite Therapiechance für Lungenkarzinompatienten
      • 58th Annual Meeting of the American Society of Hematology
        • PRESS CONFERENCES
          • Developing Novel Therapies and Unique Delivery Methods to Improve Treatment for Bleeding Crises, Leukemia
          • Revolutionizing Sickle Cell Disease Care in the United States and Abroad
          • Improved Outcomes in Leukemia, Trauma Settings with Personalized Medicine Approaches
        • Choice of ASH presentations
          • 616: Acute Myeloid Leukemia
          • Lymphoma
          • 642. CLL
          • 653. Myeloma
          • 637. Myelodysplastic Syndromes
          • 904. Outcomes Research
          • 112. Thalassemia and Globin Gene Regulation
        • Interviews Best of ASH (Multiples Myelom, Lymphome)
      • Zürich, 25. November 2016: 6. Treffen von Krebspatientinnen und -patienten
      • ESMO-Congress, Oct 07-11, 2016 - Copenhagen, Denmark
        • Press Conferences
          • Friday 7 October - Opening Press Conference
          • Saturday 8 October Press Conference 1: Late Breaking Trials
          • Sunday 9 October Press Conference 2: Late Breaking Trials
          • Monday 10 October Press Conference 3: Late Breaking Trials
        • More Highlights
          • Metastatic Colorectal Cancer
      • Cancer Center Zürich First Zurich Immuno-Oncology Symposium
        • Essentials of tumour immunology and immunotherapies
        • Clinical results, patient cases and future developments I
        • Clinical results, patient cases and future developments II
        • Clinical results, patient cases and future developments III
        • Management of toxicities
        • Radiotherapy
      • Das elektronische Patientendossier als zentrales Instrument der interprofessionellen Zusammenarbeit in integrierten Versorgungsorganisationen
      • WCGIC - 18th World Congress on Gastrointestinal Cancer
        • Metastatic & non-metastatic Colorectal Cancer
          • Statements Ulrich Güller, Andreas Wicki, Thomas Winder
        • ESMO PRESS RELEASES
          • Regorafenib shows significant survival gains in refractory liver cancer
          • Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo
          • Chemoradiotherapy after surgery for gastric cancer shows similar outcomes to post-operative chemotherapy.
          • Anti-PD-L1 immunotherapy shows response in microsatellite-stable metastatic colorectal cancer in combination with MEK inhibition
        • Satellite Symposia
          • Developing a continuum of care for patients with metastatic pancreatic cancer: A case study-based debate
          • mCRC Myth-Busters reloaded: More facts for optimal patient benefit!
      • Zürich, 1. Juli 2016: 5. Treffen von Krebspatientinnen und -patienten
      • Bern, Donnerstag 29. Juni 2016: Den Patienten integrieren - ein Symposium der Nationale Strategie gegen Krebs:
      • The 21st EHA Annual Congress
        • EHA Highlights presented at the press conference
          • Friday June 10
          • Saturday June 11
      • 36. Jahrestagung Deutsche Gesellschaft für Senologie 25.–28. Mai 2016, Dresden
        • Das Wichtigste vom Tage
        • Lunchsymposium: Genomic Health – Oncotype DX
        • Interviews
      • SENOLOGIE update 2016
        • Diagnostik - Moderation: M. Bürge, Zürich
        • Operative Therapie - Moderation: C. Tausch, Zürich
        • Über- oder Untertherapie? - Moderation: D. Fink, Zürich
        • Update Onkologie - Moderation: H-J. Senn, St. Gallen
        • Varia - Moderation: E. Saurenmann, Zürich
      • ELCC 2016 | European Lung Cancer Conference - ESMO
        • News
          • Osimertinib given as first-line treatment may alter biology of EGFR mutated non-small-cell lung cancer
          • Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma
          • Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy
          • Studies confirm benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer
        • Interviews
      • 3rd Gastrointestinal Cancer Conference
        • Thursday March 10
          • Session 1: Cystic Neoplasms of the Pancreas
          • Session 2: Biliary Tract - Extrahepatic Cholangiocarcinoma I
          • Keynote I: Molecular biology of pancreatic cancer
          • Session 3: Biliary Tract - Extrahepatic Cholangiocarcinoma II
          • Session 4: Cancer of the Ampulla of Vater
        • Friday March 11
          • Session 5: Understanding Pancreatic Cancer
          • Session 6: Resectable Pancreatic Cancer
          • Satellite symposium organized by Celgene
          • Session 7: Borderline Resectable Pancreatic Cancer
          • Session 8: Improving Outcome in Pancreatic Cancer
      • Symposium Nationale Strategie gegen Krebs:
      • WEF DAVOS: Cancer Moonshot: A Call to Action
  • Livecasts & Kongresskalender
    • Livecast
    • Kongresskalender 2018
    • Kongresskalender 2019
  • Drugs oral & i.v., Guidelines, Interaktionen
    • Orale Krebstherapeutika
      • orale Wirkstoffe A
      • orale Wirkstoffe B
      • Orale Wirkstoffe C
      • Orale Wirkstoffe D
      • Orale Wirkstoffe E
      • Orale Wirkstoffe G
      • Orale Wirkstoffe H
      • Orale Wirkstoffe I
      • Orale Wirkstoffe L
      • Orale Wirkstoffe Ν
      • Orale Wirkstoffe O
      • Orale Wirkstoffe P
      • Orale Wirkstoffe R
      • Orale Wirkstoffe S
      • Orale Wirkstoffe T
      • Orale Wirkstoffe V
    • Wirkstoffe
      • Melden Sie fehlende Wirkstoffe
      • Acronyme
      • ALK-Inhibitors
      • Wirkstoffe A
      • Wirkstoffe B
      • Wirkstoffe C
      • Wirkstoffe D
      • Wirkstoffe E
      • Wirkstoffe F
      • Wirkstoffe G
      • Wirkstoffe H
      • Wirkstoffe I
      • Wirkstoffe L
      • Wirkstoffe M
      • Wirkstoffe N
      • Wirkstoffe O
      • Wirkstoffe P
      • Wirkstoffe Q
      • Wirkstoffe R
      • Wirkstoffe S
      • Wirkstoffe T
      • Wirkstoffe V
      • Wirkstoffe Z
    • Behandlungsguidelines
    • Journal of Oncoletter
    • The Cancer Cell Line Encyclopedia
    • Texte zur Medizinischen Onkologie aus dem Swiss Medical Forum
    • Oncologic emergencies
    • Interaktionsprüfungen
    • Krebserkrankungen (Entstehung & Verlauf)
      • Krebserkrankungen B
      • Krebserkrankungen D
      • Krebserkrankungen E
      • Krebserkrankungen G
      • Krebserkrankungen H
      • Krebserkrankungen L
      • Krebserkrankungen M
      • Krebserkrankungen N
      • Krebserkrankungen P
      • Krebserkrankungen S
    • Wissenschaftlicher Beirat Oncoletter
  • Nebenwirkungen & Behandlungs- vorschläge
    • Symptome
      • Allgemeine Störungen
        • Fatigue
        • Fieber/Infektion
        • Ödeme
        • Schmerzen
        • Stimmungsschwankungen
      • Atmungsorgane
        • Dyspnoe
        • Epistaxis/Nasenbluten
        • Pleuraerguss
      • Augen
        • Konjunktivitis
        • Periorbitale Oedeme
        • Sehstoerungen
      • Blut- und Lymphsystem
        • Anaemie
        • Lymphopenie
        • Neutropenie
        • Thrombozytopenie
      • Gastrointestinale Störungen
        • Abdominalschmerz
        • Diarrhoe
        • Dyspepsie
        • Mukositis/Stomatitis
        • Nausea und Erbrechen
        • Obstipation
      • Haut
        • Aktinische Keratose
        • Alopezie
        • Hand-Fuss-Syndrom
        • Hyperkeratose
        • Photosensivitätsreaktion
        • Plattenepithelkarzinom der Haut
        • Praevention von Pruritus, Rash, Desquamation
        • Pruritus
        • Rash, papulopustulöse, follikuläre Exantheme
        • Seborrhoische Keratose
        • Sonnenbrand
        • Trockene Haut
      • Herz, Gefässe
        • Arterielle Hypertonie
        • Blutungen
        • Herzinsuffizienz
        • Hitzewallungen
        • Verminderung der linksventrikulären Auswurfsfraktion (LVEF)
      • Leber und Galle
        • Dosierungsempfehlungen oraler TKI/mTor-Inhibitoren bei Leberdysfunktion
        • Gamma-Glutamyl-Transferase
      • Muskelskelettsystem
        • Arthralgien
        • Knochenschmerzen
        • Muskelschwaeche
        • Muskelverhaertungen und Muskelkraempfe
        • Muskuloskelettale Beschwerden/Schmerzen in den Extremitaeten/Gliederschmerzen
        • Myalgie/Muskelschmerzen
        • Rueckenschmerzen
      • Nervensystem
        • Dysgeusie
        • Insomnie
        • Kopfschmerzen
        • Neuropathie/Polyneuropathie
        • Reversible posteriore Leukenzephalopathie
      • Niere und ableitende Harnwege
        • Harnwegsinfekt
      • Stoffwechsel- und Ernährungsstörungen
        • Amylase-/Lipasewerte
        • Anorexie
        • Cholesterol- oder Triglyzeridwerte
        • Gewichtszunahme
        • Glucosewerte
        • Hypokaliämie
        • Hypokalzämie
        • Hypophosphatämie
        • Hypothyreose
    • Referenzen
    • Nutzungsbestimmungen
  • Organisationen
    • Fachgesellschaften
    • Info für PatientINNen
    • Netzwerke
 
Navigation überspringen

Navigation einblenden

 
Navigation überspringen
  • Kongressberichte & Archiv
    • SABCS - 41th Annual San Antonio Breast Cancer Symposium
      • Press Conferences
        • Wednesday, Dec. 5, Press Conference 1
        • Wednesday, Dec. 5, Press Conference 2
        • Thursday, Dec. 6 Press Conference
        • Friday, Dec. 7 Press Conference
      • Schweizer Poster am SABCS
      • Interviews - Breast Cancer
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Achim Rody, Lübeck
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle/Saale
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Priv.-Doz. Dr. med. Hans-Christian Kolberg in Bottrop
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Sibylle Loibl, Frankfurt
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. Rachel Würstlein, München
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Jörg Schilling, Berlin
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Priv.-Doz. Dr. med. Hans-Christian Kolberg, Bottrop
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Lothar Müller, Onkologie Unterems
      • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
      • Round Table mit Brustkrebs Deutschland e.V.
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
    • American Society of Hematology (ASH) 60th Annual Meeting and Exposition
      • Statements & Opinions from some Highlights of the Conference
      • Press Briefings
        • Saturday December 1
          • Improving Sickle Cell Disease Outcomes in the U.S. and Africa
          • Major Trials Show Benefits of New Therapy Regimens for Cancer and Blood Disorders
          • CAR T-Cell Therapies: New Research and Updates from Pivotal Trials
        • Sunday December 2
        • Monday December 3
          • Late-Breaking Abstracts - Non-Malignant
          • Late-Breaking Abstracts - Malignant
      • Late-Breaking Abstracts Session
      • Myeloma: Therapy and upfront autologous Transplantation
        • Novel Antibody Combinations in Myeloma
        • Novel Targeted Combinations in Myeloma
        • Antibodies and Targeted Therapies
        • Novel Proteasome Inhibitors
        • Immunotherapies in Plasma Cell Disorders
        • Immunotherapy
        • Upfront Autologous Transplantation
      • Choice of Myeloma Posters
      • Acute Myeloid Leukemia - Clinical Studies
        • Immunotherapy and New Agents
        • Minimal Residual Disease and Genetic Characterization
        • Maintenance after Allogeneic Stem Cell Transplant and Management of Refractory/Relapsed AML
      • Acute Myeloid Leukemia - Commercially Available Therapy, excluding Transplantation:
        • Optimal Induction and Re-Induction Regimens For Acute Myeloid Leukemia
        • Targeted Therapy For Adults Diagnosed With Acute Myeloid Leukemia
      • Acute Myeloid Leukemia - Novel Therapy, excluding Transplantation
        • Combination Therapy
        • Targeted Therapy
        • New Treatment Strategies
        • Immunotherapy
      • Acute Lymphoblastic Leukemia: Clinical Studies & Therapy Excluding Transplantations
        • Improving Outcomes with Cellular Therapy
        • Improving Frontline Therapy in ALL
        • Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next?
        • Targeted Therapy in ALL: Immunotherapy and Beyond
      • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
        • Prognostic Markers and Therapies in Mantle Cell Lymphoma and Waldenstrom's Macroglobulinemia
        • Novel Therapies and Prognostic Assessment in Hairy Cell Leukemia and Indolent Non-Hodgkin Lymphoma
        • Antibodies, Immunomodulators, and BTK Inhibitors in Indolent NHL
      • Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
        • Immunotherapy and Targeted Strategies
        • Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches
        • T Cell Lymphoma: Chemotherapy and Targeted Approaches
      • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials
        • Immunotherapy
        • New Agents
        • Initial Treatment
      • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies
        • Outcomes With CD19 CAR T Therapy and Checkpoint Blockade in the Real World Setting
        • Prognostic Biomarkers and Molecular Signatures for Risk Stratification
        • Population Based Outcomes in Aggressive Lymphoma
        • Outcomes Of Lymphoma In The Elderly
      • Chronic Myeloid Leukemia: Therapy
        • Epidemiology, Prognosis, and Real Life Care
        • First Line Trials and Prognostic Factors of Treatment-Free Remission
        • TFR Failure, Resistance, and New Drug Development
      • Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics, Prognosis and Prediction
        • Novel Therapeutics I
        • Novel Therapeutics II
        • Prognosis and Prediction
      • CLL: Therapy, excluding Transplantation:
        • Measurable Residual Disease in CLL: Moving Towards a Cure
        • Cellular Therapy and Immunomodulation in CLL
        • Advances in CLL Using Novel Combination Therapy
      • Health Services & Outcome Research—Malignant Diseases
      • Clinical Trials for Hemophilia and Using CAR T Cells
      • Thalassemia and Globin Gene Regulation
    • Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
    • ESMO 2018 Congress
      • Press Briefings
        • Breast Cancer
        • Ovarian Cancer
        • Prostate & Kidney Cancers
        • Head & Neck Cancer
        • All ESMO 2018 Press Releases
      • Interviews
        • Interviews - Breast Cancer
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Sven Mahner, München
        • Statement Summary GIT-Cancers
        • Statements Colorectal Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Gastric Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Lung Cancer
        • Statement Renal Cell Carcinoma
      • Links to selected presentations and abstracts
        • Presidential Sessions
          • Presidential Session 1
          • Presidential Session 2
          • Presidential Session 3
        • Selection of Posters
          • 464P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
          • 1290P - Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): experience from an ad hoc expanded access program (EAP)
          • 509P - Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): a FIRE-3 analysis
          • 481P - Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial
          • 549P - Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: the plasma RAS wild type “window of opportunity”
          • 1068P - Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), a phase Ib – randomized phase II study versus single agent MTX
    • Cancer Academy - Blut- und Lymphdrüsenkrebs
    • Comprehensive Cancer Center Zürich: Third Zurich Immuno-Oncology Symposium
      • Keynote address
      • Clinical results, patient cases and future developments I
      • Clinical results, patient cases and future developments II
      • Clinical results, patient cases and future developments III
      • Developments in immunotherapy
    • 20th World Congress on Gastrointestinal Cancer (WCGIC 2018)
      • Session I: Welcome with Selected Abstracts
      • Session II: Cancer of the Pancreas and Biliary Tract - Selected Abstracts
      • Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer
      • Pancreatic Cancer: Poster Session
      • Session VII: Gastric Cancer: Presentation of selected abstracts
      • Session VIII: Diseases and Cancers of the Liver: Presentation of a selected abstract
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer
      • Session XX: Colorectal Cancer: Presentation of selected abstracts
    • 23rd Congress of EHA
      • Presidential Symposium
      • Plenary Session Abstracts
      • Press Briefings
        • Press Briefing Day 1
        • Press Briefing Day 2
      • Important AML Presentations
        • IDHm and BCL2 inhibitors in AML
        • One AML Poster
      • Important CLL Presentations
      • Important Multiple Myeloma Presentations
        • Advances in front-line treatment of newly diagnosed multiple myeloma
        • New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders
        • Multiple Myeloma Poster Presentations
        • One Multiple Myeloma Late Breaking Abstract
      • Important Lymphoma Presentations
      • Thalassemia (2 Presentations) & MDS (1 Presentation)
    • Annual Meeting of the American Society of Clinical Oncology 2018
      • Highlights of the day
        • Sunday
        • Monday
        • Tuesday
      • Press Briefings
        • May 16 Presscast
        • Press Briefing 1 Friday June 1:
        • Press Briefing 2 Saturday June 2:
        • Press Briefing 3 Sunday June 3:
        • Press Briefing 4 Monday June 4:
      • Breast Cancer
        • Breast Cancer News from Oral Sessions
        • Breast Cancer News from Poster Sessions
        • Breast Cancer News Interviews
      • Colon Cancer
        • Colon Cancer News from Poster Sessions
      • Lung Cancer
        • Lung Cancer News from oral sessions
      • Lymphoma
        • Lymphoma News Oral Sessions
        • Lymphoma News Poster Sessions
      • Merkel-Cell Carcinoma
      • Myeloid Diseases
        • Myeloid Diseases News from Oral Sessions
        • Myeloid Diseases News from Poster Sessions
      • Other Hematologic Malignancies
      • Pancreatic Cancer
        • Pancreatic Cancer News from Oral Sessions
        • Pancreatic Cancer News from Poster Sessions
      • Urologic Cancers
        • Renal Cancer
    • ESMO Preceptorship on Colorectal Cancer 2018
    • SENOLOGIE update 2018
      • Prophylaktische Mastektomie - Moderation: M. Knauer, St. Gallen
      • Psychosoziale Konsequenzen des Mammakarzinoms - Moderation: E. Sarasin, Zürich
      • Update Systemtherapie - Moderation: U. Breitenstein, Zürich
      • Varia - Moderation: E. Saurenmann, Zürich
    • Cancer Academy - Darmkrebs
    • AACR Annual Meeting 2018, April 14-18,
      • Highlights presented at the Press Conference Sunday, April 15
      • Highlights presented at the Press Conference Monday, April 16
      • Highlights presented at the Press Conference Tuesday, April 17
    • ELCC 2018 (European Lung Cancer Congress)
      • Highlights - Press Releases
      • Interviews
        • Conference Highlights
        • Interviews in Cooperation with the Video Journal of Oncology - Part 1
      • SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
    • 11th European Breast Cancer Conference (EBCC-11)
      • Press conferences
      • Important News
      • Interviews
        • PD Dr. med. Christian Kolberg, Bottrop
        • Prof. Dr. med. Thorsten Kühn, Esslingen
        • Prof. Dr. med. Nadia Harbeck, München
    • St. Gallen International Gastrointestinal Cancer Conference Primary Therapy of Early GI Cancers -
      • Session 1: Oesophago-Gastric Cancer: One Disease or Separate Entities?
      • Session 2: Treatment of Oesophago-Gastric Cancer: Setting the Stage – Who Benefits from Multimodal Therapy
      • Session 3: Treatment Modalities for Oesophago-Gastric Cancer
      • Session 4: Special situation I: Signet Ring Cell Cancer
      • Keynote: Hereditary Gastric Cancer
      • New Therapy Options by metastatic Colorectal Cancer
      • Session 5: Special situation II: Limits of Curative Approaches to Metastatic Oesophago-Gastric Cancer
      • Session 6: Ready for Practice?
      • EORTC Gastrointestinal Tract Cancer Group:
    • Cancer Academy - Prostatakrebs
    • Promoting Self-efficacy with Digital Tools
      • Welcome (German)
      • Promoting patients’ self-efficacy: How can it be successful? (German)
      • United Kingdom’s perspective on the use of digital solutions to improve cancer patients’ self-efficacy
      • Presentation of selected digital and patient-oriented applications
        • Consilium: Patient-centered communication for improved self-efficacy and quality of life
        • STREAM – Ein online Programm zur Unterstützung bei Belastung während einer Krebserkrankung
        • Symptom Navi: Förderung des Selbstmanagements von Symptomen bei Krebs
        • Entspannung und Achtsamkeit für Krebspatienten mit Hilfe einer App (CanRelax)
        • FertiOnco – an online approach to facilitate decision making in young female cancer patients regarding fertility preservation
      • The use of patient-reported outcomes to improve outcomes and quality in cancer care
      • Digital solutions for cancer patients: reach, (cost-) effectiveness and implementation
      • Discussion and Closing remarks (German)
    • Gastrointestinal Cancers Symposium Jan 18-20, 2018 San Francisco, California
      • Cancers of the Esophagus and Stomach
      • Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
        • Videostatements
        • Studies presented in oral sessions
        • Posters
        • Posters
      • Cancers of the Colon, Rectum, and Anus
        • Videostatement
        • Studies presented in oral sessions
        • Choice of Posters
    • 59th ASH Annual Meeting and Exposition
      • Late-Breaking Abstracts Session
      • AML
        • Oral Sessions
          • Acute Myeloid Leukemia: Clinical Studies: Advances in Frontline Therapy: Induction, Consolidation, and Maintenance
          • Acute Myeloid Leukemia: Clinical Studies: Novel Therapies for AML and APL
          • Acute Myeloid Leukemia: Clinical Studies: Risk Factors and Response-Adapted Personalized Medicine
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Emerging Molecularly-Targeted Therapies in AML
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Therapies for Elderly Patients with AML
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targeted and Immune-based Approaches in the Treatment of AML
      • Multiple Myeloma
        • Oral Sessions
          • Myeloma: Therapy, excluding Transplantation: Upfront Therapy for Multiple Myeloma: Induction and Maintenance
          • Myeloma: Therapy, excluding Transplantation: Immunotherapy in Myeloma and Amyloid
          • Studies in Relapsed and Refractory Multiple Myeloma
          • Myeloma: Therapy, excluding Transplantation I
          • Myeloma: Therapy, excluding Transplantation II
        • Choice of Posters
      • Lymphoma
        • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Clinical Studies: Mantle Cell Lymphoma, New Therapies
          • Indolent Lymphomas, Novel Therapies, and Diagnostics
          • Follicular Lymphoma, First Line
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Novel Agents and Upfront Approaches
          • Immune-Based Therapeutic Approaches
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Predicting Efficacy and Safety of CAR-T cells and Checkpoint Blockade
          • Outcomes in Rare Entities: HTLV-1 ATLL, Gray Zone Lymphoma, Primary CNS Lymphoma, and Intravascular DLBCL
          • Molecular Characterization of Diffuse Large B Cell Lymphoma
          • PET-Guided Therapy and Prognostic Models in Diffuse Large B-Cell Lymphoma
        • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • Hodgkin Lymphoma Immunotherapy Studies; nodular lymphocyte predominant Hodgkin lymphoma clinical studies
          • Hodgkin Lymphoma—Chemotherapy and PET Studies
          • T-Cell Lymphoma Clinical Studies
        • CLL: Therapy, excluding Transplantation:
          • Targeting MRD Negative CLL Through Combinations of Novel Agents and Antibody
          • Targeting MRD Negative CLL with Combinations of Novel Agents and Chemoimmunotherapy Regimens, New Treatments
          • New Agents, Infections, and PET/CT
      • Press Conferences
        • Novel Approaches to Hemophilia and Venous Thromboembolism Care
        • Engineering Solutions to Treat Inherited Blood Disorders
        • Enhancing Care in Hematologic Malignancies through Targeted Therapies
        • Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies
        • Late-Breaking Abstracts
      • Interviews
        • Statement Christian Taverna, Münsterlingen
        • Statement Thorsten Zenz, Zürich
    • 40th Annual San Antonio Breast Cancer Symposium (SABCS)
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
      • Press Conferences
        • Wednesday December 6 @ 7:15 a.m.
        • Wednesday December 6 @ 12:15 p.m
        • Thursday December 7 @ 7:30 am
        • Friday December 8 @ 7:30 am
      • Interviews & Brustkrebs Deutschland Round Table & SAKK Roundtable
        • Roundtable Brustkrebs Deutschland
        • Roundtable mit Experten aus der Schweiz
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin (Kopie)
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Stefan Buchholz, Regensburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Thorsten Kühn, Esslingen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Dr. phil. Ute Berndt, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr.med. Michael Untch, Berlin-Buch
    • Cancer Academy – Hirntumoren
    • 7. Interdisziplinäres Prostatakarzinomsymposium
      • Grundlagen
      • Lokalisiertes & oligometastatisches Prostatakarzinom
      • Systemtherapien Prostatakarzinom
    • Advanced Breast Cancer 4th ESO-ESMO International Consensus Conference
    • Cancer Academy – Brustkrebs
    • ESMO 2017 Congress
      • Breast Cancer Highlights
        • Neoadjuvante Therapie bei luminalem, triple negativem oder HER2 positivem Brustkrebs
        • Luminaler Brustkrebs - wer braucht Chemotherapie?
        • CDK4-6 Inhibitoren beim metastasierten Brustkrebs
        • Abstract LBA10_PR ‘Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)’
        • Abstract 1472P_PR ‘Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients’
      • Gastrointestinal Carcinoma Highlights
        • Colorectal Cancer
          • Summary Statement
          • 593P - Quality of life (QoL) analyses in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with first-line FOLFOX-4 ± cetuximab in the phase 3 TAILOR trial
          • Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) mCRC patients treated with FOLFIRI plus cetuximab in the CAPRI-GOIM trial
        • Gastric Cancer
      • Head & Neck Cancer Highlights
        • PD Dr. med. Sacha Rothschild comments Head&Neck Cancer Studies
        • Abstract LBA45_PR ‘Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial’
        • 1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
        • 1. First line Cetuximab and Cisplatin with or without Paclitaxel/2. The observational ENCORE study: Cetuximab + platinum-based therapy
      • Lung Cancer Highlights
        • Prof. Martin Reck
        • PD Dr. AlessandraCurioni-Fontecedro
        • PD Dr. AlessandraCurioni-Fontecedro
        • Prof. Dr. med.Solange Peters
        • Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
      • Melanoma & Merkel Cell Carcinoma Highlights
        • Prof. Dr. med. Reinhard Dummer, Zurich
        • Prof. Dr. med. Olivier Michielin, Lausanne
      • Ovarian Cancer Highlights
      • Urogenital Cancer Highlights
        • Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights
        • Abstract LBA37_PR – ‘Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial’
      • Late breaking news
        • Opening Press Conference
        • LBA Press Conference: Lung cancer
        • Press Conference: Facing the challenges of life after cancer
        • LBA Press Conference: Breast cancer, Gynaecological cancers, Genito-urinary cancers
        • LBA Press Conference: Melanoma cancer
        • Wrap-Up press conference/Best of ESMO2017
    • Cancer Center Zürich Second - Zurich Immuno-Oncology Symposium
      • Welcome
      • Essentials of tumour immunology and immunotherapies
      • Clinical results, patient cases and future developments I
      • Clinical results, patient cases and future developments II
      • Clinical results, patient cases and future developments III
      • Management of toxicities
    • ESMO 19th World Congress on Gastrointestinal Cancer
      • Cancer of the Pancreas
        • Session II: Cancer of the Pancreas & bile Ducts
        • Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology
        • Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
        • Interview mit Prof. Gerald Prager, Wien
      • Colon Cancer Highlights
        • Session XIX: Colorectal Cancer
        • Prof. Dr. med. Bernhard Pestalozzi, UniversitätsSpital Zürich:
    • Die besonderen Bedürfnisse von Kindern und Jugendlichen mit Krebs
    • 14 The International Conference on Malignant Lymphoma (ICML)
      • Interviews & Introductory Press Conference
        • Introductory Press Conference
        • Lymphoma Therapy
        • Oncoletter Interviews in cooperation with VJHEMONC
      • Satellite Symposia
        • THE FIRST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
        • CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?
    • ASCO Annual Meeting 2017
      • ASCO Press Conferences
        • ASCO Annual Meeting 2017 Presscast May 17
        • ASCO Annual Meeting 2017 Presscast June 2
        • ASCO Annual Meeting 2017 Presscast June 3 Part 1
        • ASCO Annual Meeting 2017 Presscast June 3 Part 2
        • ASCO Annual Meeting 2017 Presscast June 4
        • ASCO Annual Meeting 2017 Presscast June 5
      • Online-Programm verbessert die Lebensqualität von Krebspatienten
      • Highlights Mammakarzinom
        • Brustkrebs Deutschland: Experten-Roundtable vom ASCO Annual Meeting 2017
        • HER2-positiver, primär metastasierter Brustkrebs
        • HER2-positiver metastasierter Brustkrebs
        • PARP-Inhibitoren bei Brustkrebs
        • Abemaciclib bei Brustkrebs-Hirnmetastasen
        • HER2-positiver, primär metastasierter Brustkrebs
        • Scalp-Cooling - Chemo ohne Haarverlust?
        • CDK 4-6 Inhibitoren: Palbociclib, Ribociclib, Abemaciclib
        • Ergebnisse der Aphinity-Studie für HER 2 neu-positiven Brustkrebs adjuvant
        • Stellungnahme zur Relevanz von Studienendpunkten und deren Akzeptanz am runden Tisch: Wir alle müssen umdenken!
        • Finale Ergebnisse der PlanB-Studie für klinische Hochrisikopatientinnen bzw. mit mittlerem bis hohem Risiko nach Genexpressionstest
        • Short-HER-Studie:Sind 9 Wochen Trastuzumab nicht schlechter als 1 Jahr?
        • I-Spy 2-Studie: Immuntherapie mit Pembrolizumab plus Standard neoadjuvante Therapie für Hochrisikopatientinnen
      • Highlights Ovarialkarzinom
        • LION Studie: Rolle der Lymphknotenentfernung bei Erstoperation des Eierstockkrebs
        • DESKTOP 3 Studie: Erneute OP beim Eierstockkrebs Rezidiv
        • Immuntherapie bei Vulva-, Zervix- und Ovarialkarzinom: gibt es schon Einsatzmöglichkeit?
        • PARP-Inhibitoren beim Eierstockkrebs: welcher, wann und wie lange?
      • Head & Neck Cancer Highlights
        • Highlights Head&Neck
        • Statements Sacha Rothschild, Jean Bourhis & Marco Merlano
        • Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)
      • Highlights Gastrointestinaltumoren
        • Upper GIT
        • Colon Cancer
          • Colon Cancer Highlights
          • Role of Cetuximab
        • Pancreatic Cancer
      • Haematologic Malignancies
    • ELCC 2017 Genf
    • Cancer Academy – Lungenkrebs: Früherkennung, Diagnose und Behandlung
    • SENOLOGIE update 2017
      • Radiologie - Moderation: F. Dammann, Zürich
      • Genetik - Moderation: R. Morant, Rapperswil
      • Qualitätssicherung in der Senologie - Moderation: C. Rageth, Zürich
      • Operative Therapie - Moderation: C. Tausch, Zürich
      • Das metastasierte Mammakarzionom - Moderation: A. Müller, Winterthur
      • Varia - Moderation: D. Fink, Zürich
    • 15th St.Gallen International Breast Cancer Conference
    • Symposium Thoracic Oncology – Guidelines and Beyond
      • Screening
      • Inquiring the molecular tumor characteristics
      • Shanghai meets Zürich
      • Treatment options in localized NSCLC
      • Multimodality approaches in rare thoracic tumors
      • Metastatic disease
    • Archiv 2016
      • Das elektronische Patientendossier: das Genfer Beispiel der Integration eines Spitals in eine Referenzgemeinschaft
      • IASLC 17TH WORLD CONFERENCE ON LUNG CANCER
        • Fachpressemitteilungen
          • Lungenkrebs-Weltkongress in Wien: Aktive Prävention, akkurate Diagnostik, aktuelle Fortschritte in der Behandlung
          • Mutations-Diagnostik setzt sich bei Lungenkrebs durch
          • Mikro-RNA zur Prognosebestimmung bei Mesotheliom-Erkrankungen
          • Therapeutische Impfung gegen Lungenkrebs:
          • Zweite Therapiechance für Lungenkarzinompatienten
      • 58th Annual Meeting of the American Society of Hematology
        • PRESS CONFERENCES
          • Developing Novel Therapies and Unique Delivery Methods to Improve Treatment for Bleeding Crises, Leukemia
          • Revolutionizing Sickle Cell Disease Care in the United States and Abroad
          • Improved Outcomes in Leukemia, Trauma Settings with Personalized Medicine Approaches
        • Choice of ASH presentations
          • 616: Acute Myeloid Leukemia
          • Lymphoma
          • 642. CLL
          • 653. Myeloma
          • 637. Myelodysplastic Syndromes
          • 904. Outcomes Research
          • 112. Thalassemia and Globin Gene Regulation
        • Interviews Best of ASH (Multiples Myelom, Lymphome)
      • Zürich, 25. November 2016: 6. Treffen von Krebspatientinnen und -patienten
      • ESMO-Congress, Oct 07-11, 2016 - Copenhagen, Denmark
        • Press Conferences
          • Friday 7 October - Opening Press Conference
          • Saturday 8 October Press Conference 1: Late Breaking Trials
          • Sunday 9 October Press Conference 2: Late Breaking Trials
          • Monday 10 October Press Conference 3: Late Breaking Trials
        • More Highlights
          • Metastatic Colorectal Cancer
      • Cancer Center Zürich First Zurich Immuno-Oncology Symposium
        • Essentials of tumour immunology and immunotherapies
        • Clinical results, patient cases and future developments I
        • Clinical results, patient cases and future developments II
        • Clinical results, patient cases and future developments III
        • Management of toxicities
        • Radiotherapy
      • Das elektronische Patientendossier als zentrales Instrument der interprofessionellen Zusammenarbeit in integrierten Versorgungsorganisationen
      • WCGIC - 18th World Congress on Gastrointestinal Cancer
        • Metastatic & non-metastatic Colorectal Cancer
          • Statements Ulrich Güller, Andreas Wicki, Thomas Winder
        • ESMO PRESS RELEASES
          • Regorafenib shows significant survival gains in refractory liver cancer
          • Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo
          • Chemoradiotherapy after surgery for gastric cancer shows similar outcomes to post-operative chemotherapy.
          • Anti-PD-L1 immunotherapy shows response in microsatellite-stable metastatic colorectal cancer in combination with MEK inhibition
        • Satellite Symposia
          • Developing a continuum of care for patients with metastatic pancreatic cancer: A case study-based debate
          • mCRC Myth-Busters reloaded: More facts for optimal patient benefit!
      • Zürich, 1. Juli 2016: 5. Treffen von Krebspatientinnen und -patienten
      • Bern, Donnerstag 29. Juni 2016: Den Patienten integrieren - ein Symposium der Nationale Strategie gegen Krebs:
      • The 21st EHA Annual Congress
        • EHA Highlights presented at the press conference
          • Friday June 10
          • Saturday June 11
      • 36. Jahrestagung Deutsche Gesellschaft für Senologie 25.–28. Mai 2016, Dresden
        • Das Wichtigste vom Tage
        • Lunchsymposium: Genomic Health – Oncotype DX
        • Interviews
      • SENOLOGIE update 2016
        • Diagnostik - Moderation: M. Bürge, Zürich
        • Operative Therapie - Moderation: C. Tausch, Zürich
        • Über- oder Untertherapie? - Moderation: D. Fink, Zürich
        • Update Onkologie - Moderation: H-J. Senn, St. Gallen
        • Varia - Moderation: E. Saurenmann, Zürich
      • ELCC 2016 | European Lung Cancer Conference - ESMO
        • News
          • Osimertinib given as first-line treatment may alter biology of EGFR mutated non-small-cell lung cancer
          • Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma
          • Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy
          • Studies confirm benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer
        • Interviews
      • 3rd Gastrointestinal Cancer Conference
        • Thursday March 10
          • Session 1: Cystic Neoplasms of the Pancreas
          • Session 2: Biliary Tract - Extrahepatic Cholangiocarcinoma I
          • Keynote I: Molecular biology of pancreatic cancer
          • Session 3: Biliary Tract - Extrahepatic Cholangiocarcinoma II
          • Session 4: Cancer of the Ampulla of Vater
        • Friday March 11
          • Session 5: Understanding Pancreatic Cancer
          • Session 6: Resectable Pancreatic Cancer
          • Satellite symposium organized by Celgene
          • Session 7: Borderline Resectable Pancreatic Cancer
          • Session 8: Improving Outcome in Pancreatic Cancer
      • Symposium Nationale Strategie gegen Krebs:
      • WEF DAVOS: Cancer Moonshot: A Call to Action
  • Livecasts & Kongresskalender
    • Livecast
    • Kongresskalender 2018
    • Kongresskalender 2019
  • Drugs oral & i.v., Guidelines, Interaktionen
    • Orale Krebstherapeutika
      • orale Wirkstoffe A
      • orale Wirkstoffe B
      • Orale Wirkstoffe C
      • Orale Wirkstoffe D
      • Orale Wirkstoffe E
      • Orale Wirkstoffe G
      • Orale Wirkstoffe H
      • Orale Wirkstoffe I
      • Orale Wirkstoffe L
      • Orale Wirkstoffe Ν
      • Orale Wirkstoffe O
      • Orale Wirkstoffe P
      • Orale Wirkstoffe R
      • Orale Wirkstoffe S
      • Orale Wirkstoffe T
      • Orale Wirkstoffe V
    • Wirkstoffe
      • Melden Sie fehlende Wirkstoffe
      • Acronyme
      • ALK-Inhibitors
      • Wirkstoffe A
      • Wirkstoffe B
      • Wirkstoffe C
      • Wirkstoffe D
      • Wirkstoffe E
      • Wirkstoffe F
      • Wirkstoffe G
      • Wirkstoffe H
      • Wirkstoffe I
      • Wirkstoffe L
      • Wirkstoffe M
      • Wirkstoffe N
      • Wirkstoffe O
      • Wirkstoffe P
      • Wirkstoffe Q
      • Wirkstoffe R
      • Wirkstoffe S
      • Wirkstoffe T
      • Wirkstoffe V
      • Wirkstoffe Z
    • Behandlungsguidelines
    • Journal of Oncoletter
    • The Cancer Cell Line Encyclopedia
    • Texte zur Medizinischen Onkologie aus dem Swiss Medical Forum
    • Oncologic emergencies
    • Interaktionsprüfungen
    • Krebserkrankungen (Entstehung & Verlauf)
      • Krebserkrankungen B
      • Krebserkrankungen D
      • Krebserkrankungen E
      • Krebserkrankungen G
      • Krebserkrankungen H
      • Krebserkrankungen L
      • Krebserkrankungen M
      • Krebserkrankungen N
      • Krebserkrankungen P
      • Krebserkrankungen S
    • Wissenschaftlicher Beirat Oncoletter
  • Nebenwirkungen & Behandlungs- vorschläge
    • Symptome
      • Allgemeine Störungen
        • Fatigue
        • Fieber/Infektion
        • Ödeme
        • Schmerzen
        • Stimmungsschwankungen
      • Atmungsorgane
        • Dyspnoe
        • Epistaxis/Nasenbluten
        • Pleuraerguss
      • Augen
        • Konjunktivitis
        • Periorbitale Oedeme
        • Sehstoerungen
      • Blut- und Lymphsystem
        • Anaemie
        • Lymphopenie
        • Neutropenie
        • Thrombozytopenie
      • Gastrointestinale Störungen
        • Abdominalschmerz
        • Diarrhoe
        • Dyspepsie
        • Mukositis/Stomatitis
        • Nausea und Erbrechen
        • Obstipation
      • Haut
        • Aktinische Keratose
        • Alopezie
        • Hand-Fuss-Syndrom
        • Hyperkeratose
        • Photosensivitätsreaktion
        • Plattenepithelkarzinom der Haut
        • Praevention von Pruritus, Rash, Desquamation
        • Pruritus
        • Rash, papulopustulöse, follikuläre Exantheme
        • Seborrhoische Keratose
        • Sonnenbrand
        • Trockene Haut
      • Herz, Gefässe
        • Arterielle Hypertonie
        • Blutungen
        • Herzinsuffizienz
        • Hitzewallungen
        • Verminderung der linksventrikulären Auswurfsfraktion (LVEF)
      • Leber und Galle
        • Dosierungsempfehlungen oraler TKI/mTor-Inhibitoren bei Leberdysfunktion
        • Gamma-Glutamyl-Transferase
      • Muskelskelettsystem
        • Arthralgien
        • Knochenschmerzen
        • Muskelschwaeche
        • Muskelverhaertungen und Muskelkraempfe
        • Muskuloskelettale Beschwerden/Schmerzen in den Extremitaeten/Gliederschmerzen
        • Myalgie/Muskelschmerzen
        • Rueckenschmerzen
      • Nervensystem
        • Dysgeusie
        • Insomnie
        • Kopfschmerzen
        • Neuropathie/Polyneuropathie
        • Reversible posteriore Leukenzephalopathie
      • Niere und ableitende Harnwege
        • Harnwegsinfekt
      • Stoffwechsel- und Ernährungsstörungen
        • Amylase-/Lipasewerte
        • Anorexie
        • Cholesterol- oder Triglyzeridwerte
        • Gewichtszunahme
        • Glucosewerte
        • Hypokaliämie
        • Hypokalzämie
        • Hypophosphatämie
        • Hypothyreose
    • Referenzen
    • Nutzungsbestimmungen
  • Organisationen
    • Fachgesellschaften
    • Info für PatientINNen
    • Netzwerke
 
Startseite Drugs oral & i.v., Guidelines, Interaktionen Krebserkrankungen (Entstehung & Verlauf) Krebserkrankungen B

Glossary A-Z

Navigation überspringen B D E G H L M N P S  

Krebserkrankungen B

Bauchspeicheldrüsenkrebs

Link to National Cancer Institute: What You Need To Know About™ Cancer of the Cancer of the Pancreas 

Link zu Wiki

Link zu NETDOKTOR
netdoktor.at bietet unabhängige medizinische Informationen für Patienten, Ärzte und medizinisches Fachpersonal


Bestellung von Brochuren bei der Krebsliga Schweiz
Blasenkarzinom
Link to National Cancer Institute: What You Need To Know About™ Bladder Cancer

Link zu Wiki

Link zu NETDOKTOR
netdoktor.at bietet unabhängige medizinische Informationen für Patienten, Ärzte und medizinisches Fachpersonal

Bestellung von Brochuren bei der Krebsliga Schweiz
Brustkrebs
Link to National Cancer Institute: What You Need To Know About™ Breast Cancer
Link zu Wiki
Link zu NETDOKTOR
netdoktor.at bietet unabhängige medizinische Informationen für Patienten, Ärzte und medizinisches Fachpersonal

Bestellung von Brochuren bei der Krebsliga Schweiz

Infographic detailing the link between alcohol and breast cancer

 

Navigation überspringen
  • Orale Krebstherapeutika
  • Wirkstoffe
  • Behandlungsguidelines
  • Journal of Oncoletter
  • The Cancer Cell Line Encyclopedia
  • Texte zur Medizinischen Onkologie aus dem Swiss Medical Forum
  • Oncologic emergencies
  • Interaktionsprüfungen
  • Krebserkrankungen (Entstehung & Verlauf)
    • Krebserkrankungen B
    • Krebserkrankungen D
    • Krebserkrankungen E
    • Krebserkrankungen G
    • Krebserkrankungen H
    • Krebserkrankungen L
    • Krebserkrankungen M
    • Krebserkrankungen N
    • Krebserkrankungen P
    • Krebserkrankungen S
  • Wissenschaftlicher Beirat Oncoletter
 

    News

  • SAKK - SWISS GROUP FOR CLINICAL CANCER RESEARCH

    22-11-2018 18:14

    Der Preis vom Verein zur Unterstützung von Betroffenen mit gastrointestinalen Stromatumoren (GIST) geht an Dr. med. Michael Montemurro, CHUV, Lausanne und SAKK

    Weiterlesen ...

  • Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer & Survival after Minimally Invasive Radical Hysterectomy for Early-Stage and stage IA2 or IB1Cervical Cancer 

    16-11-2018 12:09

    According to two papers published in the NEJM Minimally invasive radical hysterectomy was associated with lower rates of disease-free survival and overall survival than open abdominal radical hysterectomy among women with early-stage cervical cancer. 

    Weiterlesen ...

Newsletter

Ja  Nein 
Neu laden
Bitte geben Sie den Schriftzug ein!

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Kongressorganisatoren beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weitere Finanzierungsquellen werden bei den jeweiligen Berichten aufgeführt. Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren.

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
POSTFACH 412
CH-8201 SCHAFFHAUSEN

Mail: info[@]oncoletter.ch